Ruxolitinib, a JAK1 and JAK2 inhibitor, is widely used for the treatment of myeloproliferative neoplasms, but has been successfully used to also treat immune-mediated diseases, such as graft vs. host disease (GvHD) (15, 16) and HLH (17), based on its rapid, potent, and pleiotropic influence on the host immune system. Here, JAK2 is linked to hemophagocytic syndrome.